ArticlePloS one2015
Vaccination with Recombinant Microneme Proteins Confers Protection against Experimental Toxoplasmosis in Mice.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- A systematic review on efficiency of microneme proteins to induce protective immunity against Toxoplasma gondii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Pooled it
- Systematic review and meta-analysis of variation in Toxoplasma gondii cyst burden in the murine model.Experimental parasitology · 2019Pooled it
- HarnessingAnnals of medicine · 2026Review
- Clustering of host N-glycans by the microneme MIC1/4/6 complex licenses Toxoplasma rhoptry discharge.The EMBO journal · 2026Article
- Molecular characterization and immunoprotective potential of microneme protein 3 from Eimeria necatrix.Parasites & vectors · 2026Article
- Toxoplasmosis: Epidemiological Significance, Economic Burden, and Emerging Directions in Drug Discovery and Artificial Intelligence.International journal of microbiology · 2026Review
- Recombinant Microneme Proteins MIC1 and MIC4 fromPathogens (Basel, Switzerland) · 2025Article
- Toxoplasma WH3 Δrop18 acts as a live attenuated vaccine against acute and chronic toxoplasmosis.NPJ vaccines · 2024Article
- Evaluation of Immunodiagnostic Performances ofAnimals : an open access journal from MDPI · 2024Article
- Protective mucosal and systemic immunity induced by virus-like particles expressing Toxoplasma gondii cyst wall protein.PloS one · 2023Article
- Live-attenuated ME49Δcdpk3 strain of Toxoplasma gondii protects against acute and chronic toxoplasmosis.NPJ vaccines · 2022Article
- REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.The Journal of parasitology · 2021Review
- Article
- Evaluation of 4 merozoite antigens as candidate vaccines against Eimeria tenella infection.Poultry science · 2021Article
- Diverse Roles of TgMIC1/4/6 in theFrontiers in microbiology · 2021Review
- Protective Effect Against Toxoplasmosis inFrontiers in immunology · 2021Article
- Microneme Proteins 1 and 4 FromFrontiers in immunology · 2021Article
- Immunoinformatic analysis of immunogenic B- and T-cell epitopes of MIC4 protein to designing a vaccine candidate againstClinical and experimental vaccine research · 2021Article
- Modulation Effects ofVaccines · 2020Article
- Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Toxoplasmosis, a zoonotic disease caused by Toxoplasma gondii, is an important public health problem and veterinary concern. Although there is no vaccine for human toxoplasmosis, many attempts have been made to develop one. Promising vaccine candidates utilize proteins, or their genes, from microneme organelle of T. gondii that are involved in the initial stages of host cell invasion by the parasite. In the present study, we used different recombinant microneme proteins (TgMIC1, TgMIC4, or TgMIC6) or combinations of these proteins (TgMIC1-4 and TgMIC1-4-6) to evaluate the immune response and protection against experimental toxoplasmosis in C57BL/6 mice. Vaccination with recombinant TgMIC1, TgMIC4, or TgMIC6 alone conferred partial protection, as demonstrated by reduced brain cyst burden and mortality rates after challenge. Immunization with TgMIC1-4 or TgMIC1-4-6 vaccines provided the most effective protection, since 70% and 80% of mice, respectively, survived to the acute phase of infection. In addition, these vaccinated mice, in comparison to non-vaccinated ones, showed reduced parasite burden by 59% and 68%, respectively. The protective effect was related to the cellular and humoral immune responses induced by vaccination and included the release of Th1 cytokines IFN-γ and IL-12, antigen-stimulated spleen cell proliferation, and production of antigen-specific serum antibodies. Our results demonstrate that microneme proteins are potential vaccines against T. gondii, since their inoculation prevents or decreases the deleterious effects of the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.